294 related articles for article (PubMed ID: 31462456)
1. Isoliquiritigenin, an Orally Available Natural FLT3 Inhibitor from Licorice, Exhibits Selective Anti-Acute Myeloid Leukemia Efficacy In Vitro and In Vivo.
Cao ZX; Wen Y; He JL; Huang SZ; Gao F; Guo CJ; Liu QQ; Zheng SW; Gong DY; Li YZ; Zhang RQ; Chen JP; Peng C
Mol Pharmacol; 2019 Nov; 96(5):589-599. PubMed ID: 31462456
[TBL] [Abstract][Full Text] [Related]
2. Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia.
Alachkar H; Santhanam R; Harb JG; Lucas DM; Oaks JJ; Hickey CJ; Pan L; Kinghorn AD; Caligiuri MA; Perrotti D; Byrd JC; Garzon R; Grever MR; Marcucci G
J Hematol Oncol; 2013 Mar; 6():21. PubMed ID: 23497456
[TBL] [Abstract][Full Text] [Related]
3. Synergy of FLT3 inhibitors and the small molecule inhibitor of LIM kinase1/2 CEL_Amide in FLT3-ITD mutated Acute Myeloblastic Leukemia (AML) cells.
Djamai H; Berrou J; Dupont M; Kaci A; Ehlert JE; Weber H; Baruchel A; Paublant F; Prudent R; Gardin C; Dombret H; Braun T
Leuk Res; 2021 Jan; 100():106490. PubMed ID: 33373830
[TBL] [Abstract][Full Text] [Related]
4. Cabozantinib is selectively cytotoxic in acute myeloid leukemia cells with FLT3-internal tandem duplication (FLT3-ITD).
Lu JW; Wang AN; Liao HA; Chen CY; Hou HA; Hu CY; Tien HF; Ou DL; Lin LI
Cancer Lett; 2016 Jul; 376(2):218-25. PubMed ID: 27060207
[TBL] [Abstract][Full Text] [Related]
5. Amino alkynylisoquinoline and alkynylnaphthyridine compounds potently inhibit acute myeloid leukemia proliferation in mice.
Naganna N; Opoku-Temeng C; Choi EY; Larocque E; Chang ET; Carter-Cooper BA; Wang M; Torregrosa-Allen SE; Elzey BD; Lapidus RG; Sintim HO
EBioMedicine; 2019 Feb; 40():231-239. PubMed ID: 30686755
[TBL] [Abstract][Full Text] [Related]
6. Homoharringtonine synergizes with quizartinib in FLT3-ITD acute myeloid leukemia by targeting FLT3-AKT-c-Myc pathway.
Wang F; Huang J; Guo T; Zheng Y; Zhang L; Zhang D; Wang F; Naren D; Cui Y; Liu X; Qu Y; Luo H; Yang Y; Wei H; Guo Y
Biochem Pharmacol; 2021 Jun; 188():114538. PubMed ID: 33831397
[TBL] [Abstract][Full Text] [Related]
7. LT-171-861, a novel FLT3 inhibitor, shows excellent preclinical efficacy for the treatment of FLT3 mutant acute myeloid leukemia.
Yu Z; Du J; Hui H; Kan S; Huo T; Zhao K; Wu T; Guo Q; Lu N
Theranostics; 2021; 11(1):93-106. PubMed ID: 33391463
[No Abstract] [Full Text] [Related]
8. Discovery of a Potent and Selective FLT3 Inhibitor (
Wang J; Pan X; Song Y; Liu J; Ma F; Wang P; Liu Y; Zhao L; Kang D; Hu L
J Med Chem; 2021 Apr; 64(8):4870-4890. PubMed ID: 33797247
[TBL] [Abstract][Full Text] [Related]
9. FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia.
Long J; Jia MY; Fang WY; Chen XJ; Mu LL; Wang ZY; Shen Y; Xiang RF; Wang LN; Wang L; Jiang CH; Jiang JL; Zhang WJ; Sun YD; Chang L; Gao WH; Wang Y; Li JM; Hong DL; Liang AB; Hu J
Blood; 2020 Apr; 135(17):1472-1483. PubMed ID: 32315388
[TBL] [Abstract][Full Text] [Related]
10. MZH29 is a novel potent inhibitor that overcomes drug resistance FLT3 mutations in acute myeloid leukemia.
Xu B; Zhao Y; Wang X; Gong P; Ge W
Leukemia; 2017 Apr; 31(4):913-921. PubMed ID: 27773927
[TBL] [Abstract][Full Text] [Related]
11. Oncogenic FLT3-ITD supports autophagy via ATF4 in acute myeloid leukemia.
Heydt Q; Larrue C; Saland E; Bertoli S; Sarry JE; Besson A; Manenti S; Joffre C; Mansat-De Mas V
Oncogene; 2018 Feb; 37(6):787-797. PubMed ID: 29059168
[TBL] [Abstract][Full Text] [Related]
12. Combining structure- and property-based optimization to identify selective FLT3-ITD inhibitors with good antitumor efficacy in AML cell inoculated mouse xenograft model.
Heng H; Wang Z; Li H; Huang Y; Lan Q; Guo X; Zhang L; Zhi Y; Cai J; Qin T; Xiang L; Wang S; Chen Y; Lu T; Lu S
Eur J Med Chem; 2019 Aug; 176():248-267. PubMed ID: 31103903
[TBL] [Abstract][Full Text] [Related]
13. Proteasome inhibitors induce FLT3-ITD degradation through autophagy in AML cells.
Larrue C; Saland E; Boutzen H; Vergez F; David M; Joffre C; Hospital MA; Tamburini J; Delabesse E; Manenti S; Sarry JE; Récher C
Blood; 2016 Feb; 127(7):882-92. PubMed ID: 26286850
[TBL] [Abstract][Full Text] [Related]
14. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
Zhang W; Konopleva M; Shi YX; McQueen T; Harris D; Ling X; Estrov Z; Quintás-Cardama A; Small D; Cortes J; Andreeff M
J Natl Cancer Inst; 2008 Feb; 100(3):184-98. PubMed ID: 18230792
[TBL] [Abstract][Full Text] [Related]
15. A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with
Yamaura T; Nakatani T; Uda K; Ogura H; Shin W; Kurokawa N; Saito K; Fujikawa N; Date T; Takasaki M; Terada D; Hirai A; Akashi A; Chen F; Adachi Y; Ishikawa Y; Hayakawa F; Hagiwara S; Naoe T; Kiyoi H
Blood; 2018 Jan; 131(4):426-438. PubMed ID: 29187377
[TBL] [Abstract][Full Text] [Related]
16. Dual inhibition of Fes and Flt3 tyrosine kinases potently inhibits Flt3-ITD+ AML cell growth.
Weir MC; Hellwig S; Tan L; Liu Y; Gray NS; Smithgall TE
PLoS One; 2017; 12(7):e0181178. PubMed ID: 28727840
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of FLT3 and PIM Kinases by EC-70124 Exerts Potent Activity in Preclinical Models of Acute Myeloid Leukemia.
Puente-Moncada N; Costales P; Antolín I; Núñez LE; Oro P; Hermosilla MA; Pérez-Escuredo J; Ríos-Lombardía N; Sanchez-Sanchez AM; Luño E; Rodríguez C; Martín V; Morís F
Mol Cancer Ther; 2018 Mar; 17(3):614-624. PubMed ID: 29339551
[TBL] [Abstract][Full Text] [Related]
18. Concurrent Inhibition of Pim and FLT3 Kinases Enhances Apoptosis of FLT3-ITD Acute Myeloid Leukemia Cells through Increased Mcl-1 Proteasomal Degradation.
Kapoor S; Natarajan K; Baldwin PR; Doshi KA; Lapidus RG; Mathias TJ; Scarpa M; Trotta R; Davila E; Kraus M; Huszar D; Tron AE; Perrotti D; Baer MR
Clin Cancer Res; 2018 Jan; 24(1):234-247. PubMed ID: 29074603
[No Abstract] [Full Text] [Related]
19. Natural small molecule triptonide inhibits lethal acute myeloid leukemia with FLT3-ITD mutation by targeting Hedgehog/FLT3 signaling.
Xu Y; Wang P; Li M; Wu Z; Li X; Shen J; Xu R
Biomed Pharmacother; 2021 Jan; 133():111054. PubMed ID: 33254022
[TBL] [Abstract][Full Text] [Related]
20. Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia.
Mori M; Kaneko N; Ueno Y; Yamada M; Tanaka R; Saito R; Shimada I; Mori K; Kuromitsu S
Invest New Drugs; 2017 Oct; 35(5):556-565. PubMed ID: 28516360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
